What is ESPR's health score?

Esperion Therapeutics, Inc. (ESPR) has a TradeApes health score of 52 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ESPR's estimated fair value?

Based on our 5-year discounted cash flow model, Esperion Therapeutics, Inc.'s estimated fair value is $5.41 per share, representing a 70.1% upside from the current price. This is a model estimate, not a price target or investment recommendation.

Is ESPR undervalued or overvalued?

Our model currently rates ESPR as Undervalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

To Unlock Full Report

Create an account for unlimited access

Esperion Therapeutics, Inc. (ESPR)

Healthcare Undervalued low mixed

$3.18

Updated: 2026-07-16

TradeApes Score

Financial Strength

65 Healthy

Operating Trend

60 Healthy

Relative Value

30 Weak

Capital Allocation

55 Mixed

Risk Management

50 Mixed

Est. Fair Value $5.41

DCF Upside +70.1%

Sector Rank #4155 of 12118

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Altman Z-Score in distress zone — elevated bankruptcy risk

Unlock Full Report →

Industry Related Stocks

ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Aardvark Therapeutics, Inc. (AARD) Abivax S.A. (AAVXF) Ascend Wellness Holdings, Inc. (AAWH) AbbVie Inc. (ABBV) AbCellera Biologics Inc. (ABCL)

See all Healthcare stocks →

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.